Singapore – March 15, 2023. BluMaiden Biosciences Pte Ltd, a Singapore headquartered early-stage biotechnology platform company, announced today that the well-known IT Industry leader, Michael Gorriz, Ph.D. has joined the Company as investor and member of the board.
With over 30 years of experience in the IT industry, Dr. Gorriz is currently an Independent Non-Executive Director of Mercedes-Benz Automobile Finance Co., Ltd. in China, Non-Executive Director of mox Bank (a virtual bank in Hong Kong), Non-Executive Director of Swiss IT Security AG (an IT security service group based in Switzerland) and Kyberlife (an e-commerce marketplace start-up for life sciences, pharmaceutical, and healthcare industries headquartered in Singapore). Dr. Gorriz is also currently a Board Advisor to Axis Bank Limited in India and member of the Advisory Board of zscaler (NASDAQ: ZS), a cloud security company headquartered in San Jose, California. He is a Senior Executive Education Fellow at the National University of Singapore’s School of Computing teaching about Cloud Migration and Adoption and Digital Transformation.
From 2015 to 2021, Dr. Gorriz has served as the Chief Information Officer for Standard Chartered Group from 2015 to 2021. During his tenure, he was responsible for the systems development and technology infrastructure which underpin Standard Chartered Group’s client services. He was also responsible for defining and implementing Standard Chartered Bank’s digital and innovation agenda. Prior to joining Standard Chartered, Dr. Gorriz was Vice President and Chief Information Officer at Daimler AG where he was globally responsible for strategy, planning and development of the Daimler Group’s IT systems, as well as the operation of its technical infrastructure. During his 29 years at Daimler, Dr. Gorriz progressed through specialist research and design roles in aerospace to general management roles.
Dr. Gorriz is an industry acclaimed technology leader and has won numerous awards – including the Global CIO award of the Indian NASSCOM and is one of only three CIOs in Germany nominated to a list of the 40 most important people in IT in the last 40 years. Dr. Gorriz is a physicist and engineer by background and obtained a PhD in Engineering.
BluMaiden uses proprietary machine learning and artificial intelligence approaches through integrated computational biology platforms to explore the universe within the human microbiome. The company is focused on research, development, and future commercialization of breakthrough microbiome-derived solutions for disease tracking, prevention, and therapeutics. To deepen its drug discovery research and development and bring its health-tech business to global markets, the company is expanding its collaborative partnerships with pharma, biotech, research institutes and healthcare organizations.
The BluMaiden board now comprises Dr. Damien Keogh, Michael Tillmann, Robert Meyer, Dr. Terence Kelly and Dr. Michael Gorriz. The BluMaiden Biosciences Scientific Advisory Board includes Professor Damian O’Connell, University Distinguished Professor Kim Lewis FAAAS, Distinguished Laureate Professor Nicholas Talley AC FAHMS and Professor Stephen Simpson, AC FRS FAA.
About BluMaiden Biosciences
BluMaiden Biosciences is a small-molecule drug discovery company with advanced AI microbiome analysis platforms. Headquartered in Singapore but with a globally deployable cloud-based analytics system, the company is committed to advancing the field of microbiome research through cutting-edge solutions that improve the diagnosis and treatment of disease. With a focus on innovation and quality, BluMaiden is dedicated to improving patient outcomes through advanced microbiome analysis. For additional information, please visit: Blumaiden.com and LinkedIn.
Contact Information BluMaiden Biosciences Pte Ltd
enquires@blumaiden.com